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Symptom report scales are used in clinical practice to
monitor patient outcomes. Using them permits the defini-
tion of a minimum clinically important difference (MCID)
beyond which a patient may be judged as having responded
to treatment. Despite recommendations that clinicians routi-
nely use MCIDs in clinical practice, statisticians disagree
about how MCIDs should be used to evaluate individual
patient outcomes and responses to treatment. To address
this issue, we asked how clinicians actually use MCIDs to
evaluate patient outcomes in response to treatment. Sixty-
eight psychiatrists made judgments about whether hypothe-
tical patients had responded to treatment based on their
pre- and posttreatment change scores on the widely used
Positive and Negative Syndrome Scale. Psychiatrists were
provided with the scale’s MCID on which to base their judg-
ments. Our secondary objective was to assess whether
knowledge of the patient’s genotype influenced psychiatrists’
responder judgments. Thus, psychiatrists were also infor-
med of whether patients possessed a genotype indicating
hyperresponsiveness to treatment. While many psychiatrists
appropriately used the MCID, others accepted a far lower
posttreatment change as indicative of a response to treat-
ment. When psychiatrists accepted a lower posttreatment
change than the MCID, they were less confident in such
judgments compared to when a patient’s posttreatment
change exceeded the scale’s MCID. Psychiatrists were also
less likely to identify patients as responders to treatment if
they possessed a hyperresponsiveness genotype. Clinicians
should recognize that when judging patient responses to
treatment, they often tolerate lower response thresholds than
warranted. At least some conflate their judgments with infor-
mation, such as the patient’s genotype, that is irrelevant to a
post hoc response-to-treatment assessment. Consequently,
clinicians may be at risk of persisting with treatments that
have failed to demonstrate patient benefits. Key words:
quality of care; patient decision making; clinical practice
guidelines; managed care. (MDM Policy & Practice
2016;1:1–7)
Acrucial task in clinical practice is evaluatingwhether a patient has responded to treatment.1
If a patient is failing to respond, the potential side
effects of continued treatment can outweigh its ben-
efits.1 Persisting with an ineffective treatment also
delays the provision of more effective alternatives.
On the other hand, failure to detect a patient’s
response to treatment can lead to the termination of
a potentially effective treatment plan, depriving the
patient of its benefits.2
How should clinicians decide whether a patient
has responded to treatment? In psychiatry, patient-
reported outcomes are often used to monitor symp-
toms that are not easily observed by the clinician
(e.g., hallucinations, paranoid thoughts).3 Yet psy-
chiatric symptoms are often highly variable and can
fluctuate over time, independent of any treatment
effects.4 Thus, the clinician must decide on the mini-
mum pre-/posttreatment change in the symptom
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report that indicates a treatment benefit. Symptom
report scales, such as the Positive and Negative
Syndrome Scale (PANSS) for the assessment of symp-
tom severity in schizophrenia, provide a minimum
clinically important difference (MCID) calculated on
the basis of large clinical samples.5 If a patient’s pre-
and posttreatment change in symptoms reaches or
exceeds the MCID, the clinician may judge that the
patient has responded to treatment. However, some
statisticians have argued that MCIDs based on large
clinical samples fail to account for patient variation
and measurement error at the individual level and
recommend that clinicians use a larger MCID when
assessing individual patient outcomes.6,7 The Federal
Drug Administration in the United States has made a
similar point, emphasizing that MCIDs based on large
clinical samples may not be adequate for the assess-
ment of individual patient outcomes.8
In light of the debate around how MCIDs should be
used in clinical practice, we asked how clinicians
actually use them in their assessment of individual
patient outcomes. In particular, are clinicians sensitive
to a specific scale’s MCID when using a symptom
report scale to evaluate patient outcomes? If so, do
they demand a higher or lower threshold for identify-
ing treatment benefits than the one prescribed by a
symptom report scale’s MCID? Doubts have been
raised regarding clinicians’ ability to interpret mini-
mum important clinical differences,9 generating con-
cern around recommendations for their use in clinical
decision making.2
Assessing an individual patient’s response to treat-
ment is a crucial issue for the implementation of stra-
tified medicine where treatment effects are identified
in subgroups but applied to individual patients.
While such subgroups are often defined according to
the possession of a particular genotype, Kitsios and
Kent10 have warned against the prevailing tendency
to pharmacogenetic exceptionalism—that is, to privi-
lege genetic information and give it greater weight in
clinical decision making than is warranted. Thus, our
secondary objective was to determine whether knowl-
edge of a patient’s genotype affects psychiatrists’
judgment of patient responses to treatment.
METHOD
Participants
The study protocol was approved by the ins-
titution ethics committee, and each participant pro-
vided written informed consent. Psychiatrists from
health and social care trusts in Northern Ireland,
United Kingdom, were approached during profes-
sional development meetings and were invited to
participate in the study. A total of 70 psychiatrists
(97% response rate) were recruited. Two psychia-
trists provided identical responses to all vignettes
and thus their data were excluded from the analy-
ses. Psychiatrists were asked to judge a number of
patient vignettes and outcomes and to rate their
confidence in each judgment. Fourteen psychia-
trists failed to provide all judgments, and 26
respondents failed to provide all confidence rat-
ings. We included in the analyses only complete
vignettes for which psychiatrists provided both a
responder judgment and a confidence rating.
Psychiatrists provided information about their
age, gender, specialty within psychiatry, number
of years of experience in clinical practice, and
whether or not they had completed their clinical
training. Twenty-two (33%) were trainee psychia-
trists. Across all psychiatrists, there was a mean of
10 years of clinical experience (SD = 7.6). Table 1
provides the demographic characteristics.
Materials
In collaboration with our two practicing psychia-
trists (FAO and JK), we generated hypothetical
Table 1 Demographic Characteristics (N = 68)
Variable n (%)
Gender
Male 39 (57)
Female 28 (41)
Not stated 1 (1)
Trainee psychiatrist
No 43 (63)
Yes 22 (32)
Not stated 2 (3)
Trainee general practitioner 1 (1)
Subspecialty
Psychotherapy 7 (10)
Not stated 21 (31)
General adult 22 (32)
Intellectual disability 1 (1)
Psychiatry of old age 7 (10)
Learning disability 2 (3)
Addiction 3 (4)
Generalized anxiety disorder and addiction 1 (1)
Liaison psychiatry 2 (3)
Community mental health team 1 (1)
Trainee general practitioner 1 (1)
MCMICHAEL AND OTHERS
2  MDM POLICY & PRACTICE/JULY–DECEMBER 2016
patient vignettes and patient outcomes based on the
positive subscale of the PANSS. The positive sub-
scale contains seven items (e.g., ‘‘delusions and
hostility’’), each scored by the psychiatrist on a
scale of 1 (symptom absent) to 7 (symptom
extreme). Psychiatrists were told that the MCID for
the positive subscale of the PANSS was 15.3 with a
statistical reliability (Cronbach’s alpha) of 0.73 and
a standard deviation of 6.08 based on published
studies using large clinical samples,5,9 and they
were instructed to use the provided MCID as they
saw fit in their assessment of the patient outcomes.
To aid psychiatrists’ use of the MCID, the pre- and
posttreatment scores were displayed on a visual
scale representing the full range of possible PANSS
scores (Figure 1). Shaded horizontal arrows repre-
sented the 95% confidence intervals around the
posttreatment score calculated based on the pro-
vided MCID and the associated statistical reliability
and standard deviation scores (Figure 1).
On each of 26 vignettes, psychiatrists were pre-
sented a patient’s total PANSS score prior to treat-
ment, fixed at 42, representing a high symptom
intensity,11 and the patient’s total PANSS score fol-
lowing two hypothetical treatments (Figure 1).
Hence, psychiatrists made two patient judgments
on each vignette. Posttreatment scores ranged from
3 to 26, indicating a range of improvements in posi-
tive symptoms on the PANSS. The posttreatment
range was based on typical patient improvements
reported for antipsychotic medication.12 The post-
treatment scores differed between the two treat-
ments on each vignette by as little as 1 point and by
as much as 20 points.
The vignette also identified whether the patient
possessed a specific genotype (Figure 1), which
psychiatrists were told clinical trials had demon-
strated was linked to hyperresponsiveness to treat-
ment (30% more effective than average). Only one
of the two treatments on each vignette displayed
the presence of a hyperresponsiveness genotype.
The treatments for which the patient possessed a
hyperresponsiveness genotype was not varied
between participants. Apart from the patient infor-
mation illustrated in each vignette, psychiatrists
were instructed to assume that all patients were
Figure 1 Example vignette. The visual scale, representing the full range of possible Positive and Negative Syndrome Scale (PANSS)
scores, displayed the patient’s pre- and posttreatment scores. Shaded arrows indicated the 95% confidence intervals around the
patient’s posttreatment scores based on the scale’s minimum clinically important difference (MCID) and the associated statistical relia-
bility and standard deviation scores. Vignettes indicated for which treatment the patient possessed a hyperresponsiveness genotype,
associated with a 30% increase in average treatment effectiveness. Psychiatrists were asked to judge whether they believed the patient
had responded to each treatment and provided a confidence rating for each judgment.
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otherwise identical. Based on the patient informa-
tion, psychiatrists were asked to judge whether
they believed that the patient had responded to
each treatment and to indicate their degree of confi-
dence in their judgment on a 7-point scale (1 = not
at all confident, 7 = very confident). All vignettes
were completed in one sitting, and respondents
were instructed to take as long as they felt neces-
sary to complete the study. The vignettes were pre-
sented in a randomly generated order for each
psychiatrist.
Statistical Analysis
We determined for each respondent the mini-
mum posttreatment score, past which patients were
rated as having responded to treatment. If a psy-
chiatrist’s judgments were not perfectly consistent
with a single minimum threshold, such as in the
case that a psychiatrist switched inconsistently
between judging a patient as a responder and as a
nonresponder, we estimated their most likely mini-
mum threshold.13,14 We did so by first ordering the
psychiatrist’s responder judgments according to the
patient’s change score from the lowest to the high-
est change score. We then scored each change score
as a possible ‘‘switch point,’’ such that
Score5
Number yes responses below the switch poin1
(Number of cases above and including the switch point
 Number of yes responses above and including the switch point)
Total number of cases
The change score with the lowest ‘‘switch point’’
value indicated the psychiatrist’s most likely mini-
mum accepted posttreatment change score. It fol-
lows that a candidate switch point will receive a
low probability score if few yes responses (i.e.,
responder judgments) are made below the switch
point and many yes responses are made above the
switch point. This would indicate that the corre-
sponding change score truly reflects the point at
which the psychiatrist switches from identifying
patients as nonresponders to identifying them as
responders. If, however, some yes responses are
made below the candidate switch point or some no
responses are made above the switch point, then
the probability score will increase, raising the pos-
sibility that an alternative switch point may pro-
vide a better candidate as the psychiatrist’s true
switch point.
A random effects logistic regression model was
conducted on psychiatrists’ judgments of whether
(1 = Yes) or not (0 = No) they believed each patient
had responded to treatment. This analysis included
the vignette information, the posttreatment change
score, and the presence of a hyperresponsiveness
genotype (1 = present, 0 = absent), respondents’
gender (1 = female, 0 = male), clinical training (1 =
completed training, 0 = not completed training),
and years of clinical experience.
RESULTS
Psychiatrists accepted a mean minimum post-
treatment change score of 10.43 (SD = 3.26) on
which they identified patients as having responded
to treatment. This value is significantly lower than
the 15.3 scale MCID, which the psychiatrists were
told was used in most relevant trials (one-sample t
test: t[66] = 25.09, P \ 0.001). Figure 2A confirms
that as the posttreatment change score increased
in size, more patients were identified as having
responded to treatment. The percentage of patients
identified as treatment responders increased to
almost 100% after the MCID of 15 had been
exceeded, indicating that many psychiatrists used
the MCID provided to them to identify responders to
treatment. Yet over a quarter (28%) of psychiatrists
identified patients with a posttreatment change score
of 11 or less as responders to treatment (Figure 2A).
Therefore, many psychiatrists accepted a far lower
minimum posttreatment change score than the rec-
ommended MCID of 15.
Psychiatrists were least confident in their patient
judgments when the posttreatment change score
was close to the MCID (Figure 2B). Inspection of
Figure 2B confirms that confidence ratings
increased either side of the MCID, indicating that
psychiatrists were aware of the importance of the
MCID in informing their patient judgments.
However, the mean confidence rating was 4.19 (out
of 7) at a posttreatment change score 1 point below
the MCID (i.e., change score = 14) and was signifi-
cantly lower than the mean confidence rating of
4.86 at a change score 1 point above the MCID (i.e.,
change score = 16; paired t test; t[66] = 5.16, P \
0.001), indicating that psychiatrists were more con-
fident in their patient judgments when the patient’s
change score exceeded the MCID. This difference
was even larger at 2 points below (i.e., change
score = 13; M = 4.36) and above (i.e., change score =
17; M = 5.22; paired t test; t[66] = 26.66, P\ 0.001)
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the MCID. Thus, while many patients were identi-
fied as treatment responders despite posttreatment
change scores that did not exceed the MCID, psy-
chiatrists were less confident in those judgments
than when the patient’s change score exceeded the
MCID.
Our regression analysis confirmed that larger
posttreatment change scores were associated with a
higher likelihood that patients were identified as
responders to treatment (Table 2). Yet controlling
for each patient’s posttreatment change score, the
odds of classifying a patient as a responder to treat-
ment were significantly reduced by a factor of 2.86
(1/0.35) if they possessed a genotype that indicated
hyperesponsiveness to the treatment (Table 2).
DISCUSSION
How should clinicians decide whether a patient
has responded to treatment? The Federal Drug
Administration in the United States has empha-
sized that MCIDs based on large clinical samples
may not be adequate for the assessment of individ-
ual patient outcomes.8 Symptom report scales, such
as the PANSS used to assess symptom severity in
schizophrenia,11 provide a numerical MCID, past
which clinicians may judge that a patient has
responded to treatment. In light of the debate
around how MCIDs should be used in clinical prac-
tice,6,7 we asked how clinicians actually use them
in their assessment of individual patient outcomes.
Figure 2 Percentage of judgments that patient responded (A) and mean confidence ratings (B) at each level of posttreatment change
on the Positive and Negative Syndrome Scale (PANSS). Vertical dashed bars indicate the minimum clinically important difference
(MCID) of 15.3 on which psychiatrists were instructed to base their judgments that patient responded.
Table 2 Logistic Regression Model Used to Predict Judgments of a Patient Response to Treatment
95% Confidence Interval
Variable Odds Ratio Lower Upper
Patient characteristics
Posttreatment change score 2.28* 2.13 2.44
Absence of a hyperresponsiveness genotype 2.86* 2.12 3.84
Psychiatrist characteristics
Female gender 1.89 0.59 7.30
Completed clinical training 2.83 0.86 9.39
Years of clinical experience 1.03 0.94 1.14
Participants, n 67
Degrees of freedom 5
Observations, n 3421
Note: The logistic regression analysis was a random-effects model conducted on respondents’ judgments of whether (1 = Yes) or not (0 = No) they
believed each patient had responded to treatment.
*P\ 0.0001.
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While psychiatrists were able to use the MCID
to assess patient outcomes—the percentage of
patients identified as treatment responders increased
sharply when the posttreatment change in symptoms
exceeded the MCID (Figure 2A)—many psychiatrists
accepted a lower minimum posttreatment change
score on which to identify patients as responders to
treatment. In fact, the mean minimum posttreatment
change score endorsed by psychiatrists was signifi-
cantly lower than the scale’s published MCID.
Furthermore, even though patients were often identi-
fied as having responded to treatment despite low
posttreatment changes in symptom reports, psychia-
trists were less confident in such judgments com-
pared to when a patient’s posttreatment symptom
report exceeded the scale’s MCID. These findings
imply that psychiatrists may often accept poorer
patient outcomes, despite low levels of confidence in
their own assessments. We tentatively suggest that
under some conditions clinicians may persist with
treatments that have not demonstrated sufficient ben-
efits for the patient, exposing the patient to potential
side effects of treatment, and potentially delaying the
provision of more effective alternatives.1
Clinicians have received criticism concerning
their understanding of numerical information about
patient outcomes.15 Their understanding of the
MCID is reportedly poorer than for other numerical
formats used to communicate patient outcomes.9 If
clinicians fail to correctly interpret the MCID, then
recommendations and guidelines by health authori-
ties to encourage their use in clinical practice8 may
have detrimental effects on medical decision
making. Our current findings provide a positive
message by showing that many psychiatrists used
the MCID to inform their patient judgments. The
percentage of patients identified as responders to
treatment increased toward the MCID and increased
to almost 100% when the posttreatment change
score matched or exceeded the MCID.
Our regression analysis revealed that even when
controlling for patients’ posttreatment change in
symptoms, psychiatrists were less likely to identify
a patient as having responded to treatment if they
possessed a genotype associated with a stronger
average treatment response. This is counterintuitive
for while genetic information can be informative
about the potential benefits of a treatment, it is
redundant when the patient’s actual response is
known. Our findings imply that clinicians’ judg-
ments of their patient’s response can be biased when
they are aware that a patient possesses a genotype
that is supposedly indicative of hyperresponsiveness
to treatment. Our findings in this regard accord
generally with other recent studies showing that
subjective factors can bias clinical decision
making.16 Furthermore, in studies of judgment anal-
ysis, individuals have a tendency to use all the infor-
mation provided to them, even when some of it is
irrelevant.17,18
Our study has some limitations. We presented
psychiatrists with hypothetical patient outcomes,
rather than using real patients, in order to ensure
an adequate range of patient outcomes. On each
vignette, psychiatrists evaluated a patient’s out-
come following two hypothetical treatments.
Specifically, we did not explicitly tell participants
how long the patient had been on each treatment
regime. Thus, psychiatrists may have classified a
patient as having responded to treatment when the
change score was below the MCID, due to a belief
that given enough time over the course of the treat-
ment, the participant would eventually reach or sur-
pass the MCID. Moreover, psychiatrists were
provided with a single pre- and posttreatment change
score on which to base their judgments. In clinical
practice, psychiatrists typically assess a patient on
many occasions and clinical assessments are often
made in the context of various other pieces of rele-
vant patient information.19,20 Moreover, the confi-
dence intervals around the patient’s posttreatment
score were displayed visually (Figure 1). This,
however, may have made it difficult for partici-
pants to estimate what the upper and lower
bounds of the patient’s posttreatment score were.
Future research could perhaps use numbers to
highlight the upper and lower bounds of the
patient’s change score.
Our current concern was clinicians’ use of the
MCID in their assessment of individual patient out-
comes. There is no gold standard for the interpreta-
tion of the MCID in the assessment of individual
patient outcomes. Some researchers have suggested
that a group average MCID can be applied to assess
individual patients.21 Others have argued that a
larger MCID is needed to account for individual
variation in response to treatment.6 Despite dis-
cussion among researchers about how MCIDs
should be used by clinicians to assess individual
patients, our findings show that psychiatrists often
accept posttreatment outcomes that fall below
even the lowest recommended criterion for identi-
fying patient response. Finally, future research
could investigate how psychiatrists judge patient
responses on the PANSS scale when they are
ignorant of the MCID.
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CONCLUSIONS
Psychiatrists should be cautious about how they
use an MCID when determining an individual
patient’s response to treatment and must temper
the influence of other patient information in this
regard, such as their genetic profile, especially
when the patient’s response to treatment is already
known.
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